Surgical Wire Recalled After Ninth Australian Child With Piece In Chest
This article was originally published in PharmAsia News
The Australian hospital sponsor of surgical wires made by U.S.-based Arrow International has recalled the devices after pieces of them were found in a ninth child. Mayo Healthcare, the sponsor recalled the peripheral inserted central catheter lines that used the wires to guide the device into place for injecting chemotherapy drugs and antibiotics into children in Queensland. The Therapeutic Goods Administration is investigating other PICC brands as well. A Mayo Healthcare executive emphasized the problem was human error and the wire device itself was not defective. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.